Cargando…
Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study
Transarterial chemoembolization(TACE) is the palliative treatment of choice for patients with unresectable hepatocellular carcinoma (HCC). The 242 patients prospectively enrolled in this study were diagnosed with HCC and received TACE at Sun Yat-Sen University Cancer Center between October 2014 and...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053700/ https://www.ncbi.nlm.nih.gov/pubmed/27056892 http://dx.doi.org/10.18632/oncotarget.8560 |
_version_ | 1782458465045708800 |
---|---|
author | Zhou, Zhong-Guo Chen, Jin-Bin Qiu, Hai-Bo Wang, Ruo-Jing Chen, Jian-Cong Xu, Li Chen, Min-Shan Zhang, Yao-Jun |
author_facet | Zhou, Zhong-Guo Chen, Jin-Bin Qiu, Hai-Bo Wang, Ruo-Jing Chen, Jian-Cong Xu, Li Chen, Min-Shan Zhang, Yao-Jun |
author_sort | Zhou, Zhong-Guo |
collection | PubMed |
description | Transarterial chemoembolization(TACE) is the palliative treatment of choice for patients with unresectable hepatocellular carcinoma (HCC). The 242 patients prospectively enrolled in this study were diagnosed with HCC and received TACE at Sun Yat-Sen University Cancer Center between October 2014 and March 2015. Patients were divided into study and control groups based on whether parecoxib sodium was administered postoperatively. Postoperative pain, body temperature, vomiting, changes in liver function, physical activity level, length of hospital stay, and tumor control were evaluated. Compared to the control group after propensity score matching, the study group presented less severe postoperative fever. The daily maximum temperatures in the study and control groups were 37.39 vs. 37.82°C on postoperative day 1 (P < 0.001), 37.10 vs. 37.51°C on day 2 (P < 0.001), and 36.90 vs. 37.41°C on day 3 (P < 0.001). The study group also exhibited greater physical activity (P < 0.05) and had shorter hospital stays (7.21 days vs. 7.92 days, P = 0.041). There were no differences in pain scores. Thus administration of parecoxib sodium to HCC patients after TACE effectively relieved fever, promoted postoperative recovery, and shortened the hospital stay. |
format | Online Article Text |
id | pubmed-5053700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-50537002016-10-12 Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study Zhou, Zhong-Guo Chen, Jin-Bin Qiu, Hai-Bo Wang, Ruo-Jing Chen, Jian-Cong Xu, Li Chen, Min-Shan Zhang, Yao-Jun Oncotarget Research Paper Transarterial chemoembolization(TACE) is the palliative treatment of choice for patients with unresectable hepatocellular carcinoma (HCC). The 242 patients prospectively enrolled in this study were diagnosed with HCC and received TACE at Sun Yat-Sen University Cancer Center between October 2014 and March 2015. Patients were divided into study and control groups based on whether parecoxib sodium was administered postoperatively. Postoperative pain, body temperature, vomiting, changes in liver function, physical activity level, length of hospital stay, and tumor control were evaluated. Compared to the control group after propensity score matching, the study group presented less severe postoperative fever. The daily maximum temperatures in the study and control groups were 37.39 vs. 37.82°C on postoperative day 1 (P < 0.001), 37.10 vs. 37.51°C on day 2 (P < 0.001), and 36.90 vs. 37.41°C on day 3 (P < 0.001). The study group also exhibited greater physical activity (P < 0.05) and had shorter hospital stays (7.21 days vs. 7.92 days, P = 0.041). There were no differences in pain scores. Thus administration of parecoxib sodium to HCC patients after TACE effectively relieved fever, promoted postoperative recovery, and shortened the hospital stay. Impact Journals LLC 2016-04-02 /pmc/articles/PMC5053700/ /pubmed/27056892 http://dx.doi.org/10.18632/oncotarget.8560 Text en Copyright: © 2016 Zhou et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Zhou, Zhong-Guo Chen, Jin-Bin Qiu, Hai-Bo Wang, Ruo-Jing Chen, Jian-Cong Xu, Li Chen, Min-Shan Zhang, Yao-Jun Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study |
title | Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study |
title_full | Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study |
title_fullStr | Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study |
title_full_unstemmed | Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study |
title_short | Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study |
title_sort | parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053700/ https://www.ncbi.nlm.nih.gov/pubmed/27056892 http://dx.doi.org/10.18632/oncotarget.8560 |
work_keys_str_mv | AT zhouzhongguo parecoxibpreventscomplicationsinhepatocellularcarcinomapatientsreceivinghepatictransarterialchemoembolizationaprospectivescorematchedcohortstudy AT chenjinbin parecoxibpreventscomplicationsinhepatocellularcarcinomapatientsreceivinghepatictransarterialchemoembolizationaprospectivescorematchedcohortstudy AT qiuhaibo parecoxibpreventscomplicationsinhepatocellularcarcinomapatientsreceivinghepatictransarterialchemoembolizationaprospectivescorematchedcohortstudy AT wangruojing parecoxibpreventscomplicationsinhepatocellularcarcinomapatientsreceivinghepatictransarterialchemoembolizationaprospectivescorematchedcohortstudy AT chenjiancong parecoxibpreventscomplicationsinhepatocellularcarcinomapatientsreceivinghepatictransarterialchemoembolizationaprospectivescorematchedcohortstudy AT xuli parecoxibpreventscomplicationsinhepatocellularcarcinomapatientsreceivinghepatictransarterialchemoembolizationaprospectivescorematchedcohortstudy AT chenminshan parecoxibpreventscomplicationsinhepatocellularcarcinomapatientsreceivinghepatictransarterialchemoembolizationaprospectivescorematchedcohortstudy AT zhangyaojun parecoxibpreventscomplicationsinhepatocellularcarcinomapatientsreceivinghepatictransarterialchemoembolizationaprospectivescorematchedcohortstudy |